Astrazneca begins the European exit – it will invest 50 billion dollars in the United States amid tariff threats
British giant Astrazneca said on Tuesday that it will invest 50 billion dollars in the United States amid a deadline waving the horizon of the definitions scattered by Washington.
The company said in a statement that a large part of the money will go towards building a bill of dollars in Virginia, adding that it expects 50 percent of its revenues from the United States by 2030.
The statement quoted the CEO of CEO, Pascal Soreut, as saying: “The announcement of today supports our belief in American innovation in vital pharmaceutical products.”
US President Donald Trump has opened the door to the potential targets targeting drugs, which have so far benefited from exemptions to the overwhelming fees on imports of commercial partners.
He ordered the launch of an investigation into drug imports, indicating that the fees can reach 200 percent.
The United States is a main market for the pharmaceutical industry, and Astrazeneca has already announced in April that it has begun to transfer part of its European production to the United States.
“For decades, Americans depend on the outpatient supply of major pharmaceutical products,” US Trade Minister Howard Lottenic said in a statement.
He added that the new definitions focus on “ending this structural weakness.”
The advertisement included a new factory in Virginia, which will be “the largest individual manufacturing investment”.
Other major pharmaceutical companies, which have been exempted from the 30 -year definitions, have begun in recent months to transfer investment and production to the United States.
Share this content:
Post Comment